08/15/2022 at 8:00 am
People from racial and ethnic minority populations and those from under-resourced communities are more likely than non-Hispanic White people to encounter obstacles to cancer diagnosis and treatment. In particular, social determinants of health (SDoH) may restrict access to therapies, such as immune checkpoint inhibitors (ICIs). In addition, implicit and explicit biases may impact a patient’s receipt of guideline-recommended care. Strategies to integrate multilevel interventions are needed to provide equitable access to ICI therapy, reduce risk of adverse events, and optimize patient outcomes.
In this Webcast, expert faculty will discuss the treatment obstacles many patients from underserved communities face, especially for cancer therapies, such as ICIs. They will recommend practices clinicians can implement to help their patients overcome barriers to cancer therapies. Finally, faculty will help clinicians develop strategies to make changes on a personal level and within their practice, and suggest ways to break down structural inequities within their community to improve outcomes for their patients.
At the end of this CME/CE activity, participants should be able to develop strategies to reduce health disparities in patients experiencing irAE.
Supported by educational grants from Bristol Myers Squibb and Merck Sharpe & Dohme Corp.
Physicians, PAs, nurse practitioners, nurses, nurse navigators, pharmacists, social workers, and case managers specializing in oncology, emergency medicine and/or primary care
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.Dr. Cook reports no financial relationships.
Dr. Naing reports the following financial relationships: Research Support: Amplimmune, Inc.; Arcus Biosciences, Inc.; ARMO BioSciences, Inc.; Atterocor, Inc.; Baxalta (I); Bristol Myers Squibb Company; Calithera Biosciences, Inc.; Chao Physician-Scientist Awards (I), Baylor College of Medicine; CytomX Therapeutics, Inc.; EMD Serono Inc.; Healios Oncology Nutrition, LLC; Immune Deficiency Foundation (I); ImmuneOncia Therapeutics, Inc.; Incyte; Jeffrey Modell Foundation (I); Karyopharm Therapeutics; Kymab; MedImmune; Lilly; Merck & Co., Inc.; Neon Therapeutics; NeoImmuneTech; National Cancer Institute (NCI); Novartis; Pfizer Inc.; PsiOxus Therapeutics; Regeneron Pharmaceuticals In; Surface Oncology; and TopAlliance BioSciences Inc. Other Financial or Material Support: (Travel, accommodations, expenses) ARMO Biosciences, Inc.
Dr. Velázquez Mañana reports the following financial relationships: Stock Shareholder (directly purchased): Corbus Pharmaceuticals Holdings, Inc. Other Financial or Material Support: LEAD Conference advisory committee member organized by BioAscend; Stipend from MDOutlook and Curio Science; and Travel Support from DAVA Oncology.
The following peer reviewer and CME Outfitters staff have no financial relationships:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Call us at (877) CME-PROS or (877) 263-7767.